Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Stem Cell Transplantation in MDS and Myeloproliferative Disorders
NCT00054340Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2002
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of acute graft-vs-host disease (GVHD) requiring therapy up to 2 years. Started Oct 2002; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00054340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054340.